Clinical trial
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
NCT00413218 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
- Lead sponsor
- Astellas Pharma Inc
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 8, 2007
- Completion date
- March 3, 2015
- Enrollment
- 450 (actual)
- Sites
- 113
Conditions
As the registry lists them; a condition with its own page is linked.